Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia

• Seiichi Okabe ,

  * E-mail: okabe@tokyo-med.ac.jp

  Affiliation First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

  ⨯
• Tetsuzo Tauchi,

  Affiliation First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

  ⨯
• Shinya Kimura,

  Affiliation Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan

  ⨯
• Taira Maekawa,

  Affiliation Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan

  ⨯
• Toshihiko Kitahara,

  Affiliation First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

  ⨯
• Yoko Tanaka,

  Affiliation First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

  ⨯
• Kazuma Ohyashiki

  Affiliation First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

  ⨯